We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+4.89%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$189M
AUM Growth
-$1.06M
Cap. Flow
-$5.94M
Cap. Flow %
-3.14%
Top 10 Hldgs %
89.07%
Holding
42
New
4
Increased
5
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
CFRX
ContraFect Corporation
CFRX
+$2.31M
2
HNSN
HANSEN MEDICAL, INC. COM NEW
HNSN
+$2.15M
3
COLL icon
Collegium Pharmaceutical
COLL
+$1.36M
4
ADXS
Advaxis Inc
ADXS
+$750K
5
YTEN
Yield10 Bioscience, Inc. Common Stock
YTEN
+$617K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$12.3M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$902K
3
XNCR icon
Xencor
XNCR
+$643K
4
BIIB icon
Biogen
BIIB
+$161K
5
TTHI
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
+$35K

Sector Composition

Rank Sector Weight
1 Healthcare 85.81%
2 Consumer Staples 4.04%
3 Energy 3.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MACK
26
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$523K 0.28%
5,376
– –
CELGZ
27
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$444K 0.23%
213,432
– –
CERS icon
28
Cerus
CERS
$631M
$431K 0.23%
83,000
– –
PXD
29
DELISTED
Pioneer Natural Resource Co.
PXD
$416K 0.22%
3,000
– –
BIIB icon
30
Biogen
BIIB
$29.5B
$404K 0.21%
1,000
-400
-29% -$161K
ROKA
31
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$396K 0.21%
15,231
– –
AGIO icon
32
Agios Pharmaceuticals
AGIO
$2.38B
$378K 0.2%
3,400
– –
TTHI
33
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$306K 0.16%
145,746
-5,000
-3% -$35K
XNCR icon
34
Xencor
XNCR
$1.39B
$270K 0.14%
12,300
-37,700
-75% -$643K
QTNT
35
DELISTED
Quotient Limited Ordinary Shares
QTNT
$269K 0.14%
455
– –
PBYI icon
36
Puma Biotechnology
PBYI
$422M
$251K 0.13%
2,150
– –
PQUE
37
DELISTED
PETROQUEST ENERGY INC (DE)
PQUE
$242K 0.13%
122,050
– –
CHRS icon
38
Coherus Oncology
CHRS
$219M
$217K 0.11%
7,500
– –
NXTM
39
DELISTED
NxStage Medical Inc.
NXTM
$210K 0.11%
14,700
– –
NSPR icon
40
InspireMD
NSPR
$33M
– –
0
– –
CALA
41
DELISTED
Calithera Biosciences, Inc
CALA
$141K 0.07%
+985
New +$228K
ASPX
42
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
– –
-9,000
Closed -$902K
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Birchview Capital held 42 positions worth $189M, down 0.56% from $190M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Birchview Capital withdrew a net $5.94M in Q2 2015, closing 1 position and reducing 4 holdings. Its most notable exit was AUSPEX PHARMACEUTICALS INC COM STK (DE), an estimated $902K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier, followed by Consumer Staples and Energy.

Against the trend, Birchview Capital opened a new position in ContraFect Corporation worth $2.15M.

  • Birchview Capital's largest Q2 2015 buy was ContraFect Corporation: 569 shares worth $2.15M.
  • Birchview Capital added most to HANSEN MEDICAL, INC. COM NEW in Q2 2015, an estimated $2.15M increase.
  • Birchview Capital's biggest Q2 2015 reduction was Celgene Corp, cutting an estimated $12.3M.
  • Birchview Capital fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $902K.
  • Birchview Capital's ten largest holdings make up 89% of its $189M portfolio in Q2 2015.
  • Birchview Capital opened 4 new positions and closed 1 in Q2 2015.
  • Birchview Capital's portfolio value fell 0.56% quarter-over-quarter to $189M.

Based on Birchview Capital's 13F filing for Q2 2015, filed 13 Aug 2015.